Bausch Health Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024%, Is Now Approved In Brazil

The Brazilian Health Regulatory Agency (ANVISA - Agência Nacional de Vigilância Sanitária), which oversees Bausch + Lomb's primary global eye health business, recently granted regulatory approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%.

In the United States and other territories with the similar indication, VYZULTA is recommended for lowering intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

"VYZULTA has received its eleventh regulatory approval with its approval in Brazil. To assist meet this urgent unmet medical need, we will continue to concentrate our efforts on obtaining additional regulatory approvals for this significant glaucoma treatment option, stated Thomas J. Appio, president of Bausch + Lomb/International.

Ten markets, including Argentina, Brazil, Canada, Colombia, Costa Rica, Hong Kong, Mexico, South Korea, Taiwan, Ukraine, and the United States, have now approved VYZULTA.